Generating destination analysis
Compass Direction
Earnings IntelligenceAI-Powered
Compass Score
Key Numbers
Market Cap
$1B
P/E
N/A
Revenue Growth
0.0%
Gross Margin
N/A
ROE
N/A
About Verve Therapeutics
As a small-cap biotech company trading on the NASDAQ, Verve Therapeutics has established itself, positioned as a pure-play investment vehicle for the biotech and genomics megatrend. Gene-editing approach to cardiovascular disease using base editing technology. With a $1B market capitalization and no current profitability, Verve Therapeutics has delivered declining revenues with revenue moving 0% over the past year.
Expert Coverage
Unlock Full VERV Analysis
Expert analysis and coverage for Verve Therapeutics
Or unlock everything now with Compass, $9/moPrice & Technical Analysis
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
More in Biotech & Genomics
Beam Therapeutics
Base editing platform with differentiated gene-editing pipeline.
DexCom Inc.
Continuous glucose monitoring leader expanding beyond diabetes management.
Alnylam Pharmaceuticals
RNA interference therapeutics leader with approved treatments for rare diseases.
Recursion Pharmaceuticals
AI-driven drug discovery platform using machine learning to decode biology at scale.